<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Infect. Dis</journal-id><journal-id journal-id-type="hwp">cid</journal-id><journal-id journal-id-type="publisher-id">cid</journal-id><journal-title-group><journal-title>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</journal-title></journal-title-group><issn pub-type="ppub">1058-4838</issn><issn pub-type="epub">1537-6591</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27988484</article-id><article-id pub-id-type="pmc">5215218</article-id><article-id pub-id-type="doi">10.1093/cid/ciw706</article-id><article-categories><subj-group subj-group-type="heading"><subject>Major Article</subject></subj-group></article-categories><title-group><article-title>Fixed-Dose Artesunate&#x02013;Amodiaquine Combination vs Chloroquine for Treatment of Uncomplicated Blood Stage P. vivax Infection in the Brazilian Amazon: An Open-Label Randomized, Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Siqueira</surname><given-names>Andre M.</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="AF0003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Alencar</surname><given-names>Aline C.</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Melo</surname><given-names>Gisely C.</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Magalhaes</surname><given-names>Belisa L.</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Machado</surname><given-names>Kim</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Alencar Filho</surname><given-names>Arist&#x000f3;teles C.</given-names></name><xref ref-type="aff" rid="AF0004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kuehn</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="AF0005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Marques</surname><given-names>Marly M.</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Manso</surname><given-names>Monica Costa</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Felger</surname><given-names>Ingrid</given-names></name><xref ref-type="aff" rid="AF0006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vieira</surname><given-names>Jos&#x000e9; L. F.</given-names></name><xref ref-type="aff" rid="AF0007">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lameyre</surname><given-names>Valerie</given-names></name><xref ref-type="aff" rid="AF0008">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Daniel-Ribeiro</surname><given-names>Claudio T.</given-names></name><xref ref-type="aff" rid="AF0009">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lacerda</surname><given-names>Marcus V. G.</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="AF0010">
<sup>10</sup>
</xref></contrib><aff id="AF0001"><label>1</label>
<sup>1</sup>
<institution>Funda&#x000e7;&#x000e3;o de Medicina Tropical Dr. Heitor Vieira Dourado,
</institution>
</aff><aff id="AF0002"><label>2</label>
<sup>2</sup>
<institution>Universidade do Estado do Amazonas, Manaus</institution>,
</aff><aff id="AF0003"><label>3</label>
<sup>3</sup>
<institution>Instituto Nacional de Infectologia Evandro Chagas, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Rio de Janeiro</institution>,
</aff><aff id="AF0004"><label>4</label>
<sup>4</sup>
<institution>Universidade Federal do Amazonas, Manaus, Brazil</institution>;
</aff><aff id="AF0005"><label>5</label>
<sup>5</sup>
<institution>ISGlobal, Barcelona Center for International Health Research (CRESIB), Hospital Cl&#x000ed;nic - Universitat de Barcelona, Barcelona, Spain</institution>;
</aff><aff id="AF0006"><label>6</label>
<sup>6</sup>
<institution>Swiss Tropical and Public Health Institute, Basel, Switzerland</institution>;
</aff><aff id="AF0007"><label>7</label>
<sup>7</sup>
<institution>Universidade Federal do Par&#x000e1;, Bel&#x000e9;m, Brazil</institution>;
</aff><aff id="AF0008"><label>8</label>
<sup>8</sup>
<institution>Access to Medicines Department, Sanofi , Paris, France</institution>;
</aff><aff id="AF0009"><label>9</label>
<sup>9</sup>
<institution> Instituto Oswaldo Cruz, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Rio de Janeiro</institution>, and</aff><aff id="AF0010"><label>10</label>
<sup>10</sup>
<institution>Instituto Le&#x000f4;nidas e Maria Deane, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Manaus, Brazil</institution>
</aff></contrib-group><author-notes><corresp id="c1">Correspondence: A. M. Siqueira, Instituto Nacional de Infectologia Evandro Chagas, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Av. Brasil 4365 - Rio de Janeiro, RJ, Brazil (<email>andre.siqueira@ini.fiocruz.br</email> and <email>amsiqueira@gmail.com</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>12</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>64</volume><issue>2</issue><fpage>166</fpage><lpage>174</lpage><history><date date-type="received"><day>7</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.</copyright-statement><copyright-year>2016</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract abstract-type="precis"><title>Summary</title><p>In the Brazilian Amazon, the artesunate&#x02013;amodiaquine combination was more effective in preventing <italic>Plasmodium vivax</italic> recurrence. With a favorable safety profile, this antimalarial treatment proved to be a good first-line alternative. Chloroquine resistance is probably underestimated in the area.</p></abstract><abstract><sec><title>Background.</title><p>Despite increasing evidence of the development of <italic>Plasmodium vivax</italic> chloroquine (CQ) resistance, there have been no trials comparing its efficacy with that of artemisinin-based combination therapies (ACTs) in Latin America.</p></sec><sec><title>Methods.</title><p>This randomized controlled trial compared the antischizontocidal efficacy and safety of a 3-day supervised treatment of the fixed-dose combination artesunate-amodiaquine Winthrop<sup>&#x000ae;</sup> (ASAQ) versus CQ for treatment of uncomplicated <italic>P. vivax</italic> infection in Manaus, Brazil. Patients were followed for 42 days. Primary endpoints were adequate clinical and parasitological responses (ACPR) rates at day 28. Genotype-adjustment was performed.</p></sec><sec><title>Results.</title><p>From 2012 to 2013, 380 patients were enrolled. In the per-protocol (PP) analysis, adjusted-ACPR was achieved in 100% (165/165) and 93.6% (161/172) of patients in the ASAQ and CQ arm (difference 6.4%, 95% CI 2.7%; 10.1%) at day 28 and in 97.4% (151/155) and 77.7% (129/166), respectively (difference 19.7%, 95% CI 12.9%; 26.5%), at day 42. Apart from ITT D28 assessment, superiority of ASAQ on ACPR was demonstrated. ASAQ presented faster clearance of parasitaemia and fever. Based on CQ blood level measurements, CQ resistance prevalence was estimated at 11.5% (95% CI: 7.5-17.3) up to day 42. At least one emergent adverse event (AE) was recorded for 79/190 (41x6%) in the ASAQ group and for 85/190 (44x7%) in the CQ group. Both treatments had similar safety profiles.</p></sec><sec><title>Conclusions.</title><p>ASAQ exhibited high efficacy against CQ resistant P. vivax and is an adequate alternative in the study area. Studies with an efficacious comparator, longer follow-up and genotype-adjustment can improve CQR characterization.</p><p content-type="flush left">
<bold>Clinical Trials Registration</bold>. NCT01378286.</p></sec></abstract><kwd-group><title>Keywords.</title><kwd><italic>Plasmodium vivax</italic></kwd><kwd>malaria</kwd><kwd>chloroquine</kwd><kwd>randomized clinical trial</kwd><kwd>artesunate-amodiaquine.</kwd></kwd-group><counts><page-count count="9"/></counts></article-meta></front><body><p>There were an estimated 214 million malaria episodes and 438 000 related deaths in 2015 [<xref rid="CIT0001" ref-type="bibr">1</xref>]. <italic>Plasmodium vivax</italic> is the malaria-causing parasite species with the widest geographical distribution, resulting in 2.85 billion people at risk [<xref rid="CIT0002" ref-type="bibr">2</xref>]. Studies from all <italic>P. vivax</italic> endemic areas demonstrate that this infection can progress to have severe and fatal outcomes [<xref rid="CIT0003" ref-type="bibr">3</xref>, <xref rid="CIT0004" ref-type="bibr">4</xref>], rendering the long-held belief that <italic>P. vivax</italic> is benign as no longer valid [<xref rid="CIT0005" ref-type="bibr">5</xref>].</p><p content-type="indent">Resistance to antimalarials is a major barrier for case-management and control of transmission [<xref rid="CIT0006" ref-type="bibr">6</xref>, <xref rid="CIT0007" ref-type="bibr">7</xref>] and requires constant monitoring. For more than 60 years, the mainstay of <italic>P. vivax</italic> treatment has been a combination of chloroquine (CQ) with primaquine (PQ) as an antirelapse drug [<xref rid="CIT0008" ref-type="bibr">8</xref>, <xref rid="CIT0009" ref-type="bibr">9</xref>]. This combination&#x02019;s synergistic schizontocidal effect, which is associated with the parasite&#x02019;s usually lower biomass and shorter duration of gametocytes presence compared with those of <italic>Plasmodium falciparum</italic>, may have contributed to slower development of CQ resistance in <italic>P. vivax</italic> [<xref rid="CIT0009" ref-type="bibr">9</xref>]. However, there has been an increasing number of reports of CQ resistance (CQR) in regions where this parasite is endemic [<xref rid="CIT0010" ref-type="bibr">10&#x02013;12</xref>], especially in Southeast Asia and the Pacific region [<xref rid="CIT0013" ref-type="bibr">13&#x02013;15</xref>], where 5 countries have already adopted artemisinin-based combination therapies (ACTs). these therapies provide fast parasite clearance and prevent recrudescences [<xref rid="CIT0016" ref-type="bibr">16</xref>] as first-line treatment for <italic>P. vivax</italic> [<xref rid="CIT0001" ref-type="bibr">1</xref>]. In Latin America, where <italic>P. vivax</italic> is the most prevalent species causing malaria [<xref rid="CIT0001" ref-type="bibr">1</xref>] despite recent evidence of CQR [<xref rid="CIT0011" ref-type="bibr">11</xref>, <xref rid="CIT0017" ref-type="bibr">17&#x02013;20</xref>], no studies comparing the efficacy of ACTs to that of CQ have been reported.</p><p content-type="indent">The combination of artesunate&#x02013;amodiaquine (ASAQ) against <italic>P. falciparum</italic> has been adopted in many countries and is one of the World Health Organization (WHO) prequalified antimalarials. The ASAQ fixed-dose combination (FDC) tested in this study (artesunate&#x02013;amodiaquine Winthrop, or ASAQ Winthrop) was codeveloped by DNDi and Sanofi. This formulation was shown to result in better compliance and reduced risk of emergence of <italic>P. falciparum</italic> resistance when compared with loose-dose combinations and coblisters [<xref rid="CIT0021" ref-type="bibr">21</xref>, <xref rid="CIT0022" ref-type="bibr">22</xref>]. We conducted this clinical trial in order to evaluate the efficacy and safety of the ASAQ FDC compared with that of CQ against uncomplicated <italic>P. vivax</italic> infection.</p><sec sec-type="methods" id="s1"><title>METHODS</title><sec id="s2"><title>Study Site</title><p>Our study was undertaken at Funda&#x000e7;&#x000e3;o de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD), Manaus, in the Brazilian Western Amazon region. Malaria transmission is restricted to rural areas, and <italic>P. vivax</italic> causes around 90% of malaria cases [<xref rid="CIT0023" ref-type="bibr">23</xref>]. Antimalarials are only provided in health units after diagnostic confirmation of infection. National guidelines recommend CQ (total dose of 25 mg/kg over 3 days) and PQ (0.5 mg/kg/day over 7 days) for <italic>P. vivax</italic> infection treatment and artemether&#x02013;lumefantrine or artesunate&#x02013;mefloquine for <italic>P. falciparum</italic> [<xref rid="CIT0024" ref-type="bibr">24</xref>]. Studies showed therapeutic failure rates as high as 10% with CQ monotherapy for <italic>P. vivax</italic> in 2005 [<xref rid="CIT0017" ref-type="bibr">17</xref>].</p></sec><sec id="s3"><title>Study Design</title><p>This was an open-label, randomized, noninferiority, controlled trial that compared the efficacy and safety of ASAQ (Winthrop; Sanofi, Morocco) and CQ (Farmanguinhos, Brazil) for treatment of uncomplicated <italic>P. vivax</italic> blood stage infection. The study was based on the WHO antimalarial drug efficacy protocols modified for <italic>P. vivax</italic> [<xref rid="CIT0025" ref-type="bibr">25</xref>, <xref rid="CIT0026" ref-type="bibr">26</xref>]. Patients were followed up for 42 days to assess drug efficacy and safety.</p><p content-type="indent">The ethics review board of FMT-HVD (0426/2011) and the National Brazilian Committee of Ethics (16532/2011) approved the study. All adult patients and legal guardians of children provided written informed consent. The protocol is available in the Supplementary Materials.</p></sec><sec id="s4"><title>Patients</title><p>Individuals aged &#x0003e;6 months with a body weight &#x0003e;5 kg with slide-confirmed <italic>P. vivax</italic> monoinfection, parasite density between 250 and 100 000 parasites/&#x000b5;L, and axillary temperature &#x02265;37.5&#x000b0;C or history of fever in the last 48 hours were considered eligible. Exclusion criteria included pregnant or breast-feeding women; plan of leaving the study area in the following 42 days; known hypersensitivity to 1 of the investigational products; blurred vision suggesting retinopathy; presence of at least 1 severe criterion of malaria; known severe concomitant or underlying disease; and women of childbearing potential unwilling to use an effective contraceptive method during the study.</p></sec><sec id="s5"><title>Procedures, Randomization, and Concealment</title><p>Enrolled patients were randomly assigned to 1 of the treatment arms by a study nurse through a computer-generated list that linked each patient&#x02019;s study number to an opaque zone, thus, concealing the assigned treatment arm. Neither the study doctors nor the laboratory personnel responsible for reading the slides and the polymerase chain reaction (PCR) test had access to patients&#x02019; allocation during the study.</p><p content-type="indent">ASAQ was administered as a fixed-dose combination with 3 oral formulations (25/67.5 mg, 50/135 mg, 100/270 mg) and CQ as 150-mg tablets. Dosing was based on established weight bands for each drug (<ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw706/-/DC1">Supplementary Table 1</ext-link>). Study nurses supervised all dosing at enrollment and 24 and 48 hours after. When necessary, tablets were dissolved in water and administered orally using a syringe to ensure proper dosing to children. Patients were followed on an outpatient basis. PQ was withheld until day 42 or at day of recurrence. Recurrences during follow-up were treated with fixed-dose artesunate&#x02013;mefloquine combination (Farmanguinhos, Brazil). The dose was administered a second time if vomiting occurred within 30 minutes.</p><p content-type="indent">Visits for clinical and microscopic assessments were scheduled on days 1, 2, 3, 7, 14, 28, and 42 after enrollment. Laboratory blood assessments (total blood cell count, bilirubin, glycemia, aspartate aminotransferase, alanine aminotransferase [ALT], and creatinine) were performed at enrollment and repeated on day 7 and day 28. Electrocardiograms were performed at enrollment, day 2, and day 28 for all participants aged &#x0003e;10 years and evaluated by a cardiologist. Blood samples were collected on day 7 and day of recurrence for CQ and desetylchloroquine (DCQ) blood assays, measured using high-performance liquid chromatography as previously described [<xref rid="CIT0027" ref-type="bibr">27</xref>]. The sum of CQ and DCQ blood levels was used to classify parasites as sensitive or resistance based on the 100-ng/mL cutoff level, as previously established [<xref rid="CIT0012" ref-type="bibr">12</xref>, <xref rid="CIT0026" ref-type="bibr">26</xref>, <xref rid="CIT0028" ref-type="bibr">28</xref>]. Technical problems with sample storage and collection, consisting of insufficient volume of blood for the analyses, prevented measurement of day 7 blood levels of AQ.</p><p content-type="indent">Two experienced technicians examined microscopic blood smears. Parasite density was calculated using the white cell count from the nearest total blood cell count (usually from enrollment, day 7, or day 28) [<xref rid="CIT0029" ref-type="bibr">29</xref>].</p></sec><sec id="s6"><title>Molecular Analyses</title><p>Real-time PCR was performed on filter-paper samples from enrollment or recurrences to confirm <italic>P. vivax</italic> monoinfection according to described protocols [<xref rid="CIT0030" ref-type="bibr">30</xref>]. For the genotyping procedures for comparing day 0 and recurrence samples, 3 highly polymorphic gene regions were chosen according to diversity and discriminatory potential in the region, namely, msp1F3, MS2, and MS8 [<xref rid="CIT0031" ref-type="bibr">31&#x02013;34</xref>]. As there is no standard recommendation for classifying <italic>P. vivax</italic> recurrences due to difficulties distinguishing reinfection, recrudescence, and relapse [<xref rid="CIT0035" ref-type="bibr">35</xref>, <xref rid="CIT0036" ref-type="bibr">36</xref>], we adapted the classification method recommended by WHO for <italic>P. falciparum</italic> [<xref rid="CIT0025" ref-type="bibr">25</xref>]. For each recurrence, samples were classified as homologous if at least 1 allele for each loci investigated was detected in both paired samples and as heterologous if all alleles for a given marker were different. A recurrent homologous <italic>P. vivax</italic> episode could derive either from a recrudescent-resistant parasite or from a dormant liver stage. For this study, we chose to treat these events as treatment failures after correction. Further details on the molecular characterization are provided in the <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw706/-/DC1">Supplementary Materials</ext-link>.</p></sec><sec id="s7"><title>Statistical Analyses and Sample Calculation</title><p>We assumed a 90% efficacy rate for CQ within 28 days [<xref rid="CIT0017" ref-type="bibr">17</xref>] and 95% efficacy for ASAQ [<xref rid="CIT0037" ref-type="bibr">37</xref>]. The noninferiority margin was defined at 5%, considering alpha at 2.5% for the unilateral test and power of 90%, a sample size of 145 individuals per arm, increased to 190 after adding 15% loss to follow-up and 10% risk of mixed infections.</p><p content-type="indent">The primary endpoint was genotype-adjusted adequate cure and parasitological response (ACPR) at day 28 for the per-protocol (PP) population. Secondary endpoints, performed in both the PP and intention-to-treat (ITT) populations, included crude ACPR on day 28 and ACPR on day 14 and day 42, prevalence and incidence of positive asexual parasitemia and gametocyte carriage, hemoglobin changes from baseline, and incidence of adverse events (AEs).</p><p content-type="indent">Noninferiority was demonstrated if the lower bound of the 95% confidence interval (CI) of the risk difference between the 2 arms was greater than &#x02212;0.05 in the PP population populations. The CIs were calculated using normal approximation, with continuity correction in the Wald limits applied in the case of empty cells [<xref rid="CIT0038" ref-type="bibr">38</xref>]. If noninferiority was shown, a 2-sided Fisher exact test to assess superiority was performed in the ITT population. This analysis was performed despite not being described in the protocol-following recommendation [<xref rid="CIT0039" ref-type="bibr">39</xref>] and due to the large difference observed. Both the PP and ITT are presented.</p><p content-type="indent">Time to recurrence was assessed by survival curves using the Kaplan-Meier estimator and log-rank tests. The proportion of patients with negative blood slides for both asexual and sexual parasites and fever clearance was analyzed at days 1, 2, and 3. A general estimating equation (GEE) model [<xref rid="CIT0040" ref-type="bibr">40</xref>] was used to compare person-week gametocyte densities during follow-up; this consisted of a univariate analysis with robust standard errors, with the number of gametocyte-positive slides per individual per week as the outcome.</p><p content-type="indent">Anemia was graded according to WHO references [<xref rid="CIT0041" ref-type="bibr">41</xref>]. Neutropenia and elevation of ALT were considered AEs of special interest [<xref rid="CIT0042" ref-type="bibr">42&#x02013;44</xref>]. An independent data monitoring committee comprised of 3 renowned experts reviewed the study protocol and evaluated the results of efficacy and safety analyses. An additional analysis was performed only for the CQ arm to investigate a possible association between delayed parasite clearance (&#x0003e;72 hours) as the dependent variable and risk of recurrence, the outcome variable, using logistic regression.</p></sec></sec><sec id="s8"><title>RESULTS</title><p>Patients were enrolled between January 2012 and June 2013 (<xref ref-type="fig" rid="F1">Figure 1</xref>). Most patients were adult males and resided in the nonactive transmission Manaus urban area (<xref ref-type="table" rid="T1">Table 1</xref>).</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Flowchart of the study. *Some patients had more than 1 reason for exclusion. Abbreviations: ASAQ, artesunate&#x02013;amodiaquine; CQ, chloroquine; PCR, polymerase chain reaction; PP, per protocol; <italic>P. vivax</italic>, <italic>Plasmodium vivax</italic>.</p></caption><graphic xlink:href="clinid_ciw706_f0001"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Demographic and Disease Characteristics at Baseline in the Intention-to-Treat Population</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="center" valign="bottom" rowspan="1" colspan="1">Artesunate&#x02013;Amodiaquine (n = 189)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Chloroquine (n = 190)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">136 (72.0%)</td><td align="center" rowspan="1" colspan="1">144 (75.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, y</td><td align="center" rowspan="1" colspan="1">35.7 (1&#x02013;68; 16&#x000b7;4)</td><td align="center" rowspan="1" colspan="1">34.7 (1&#x02013;74; 15&#x000b7;9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;6</td><td align="center" rowspan="1" colspan="1">7 (3.7%)</td><td align="center" rowspan="1" colspan="1">7 (3.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">6&#x02013;14</td><td align="center" rowspan="1" colspan="1">10 (5.3%)</td><td align="center" rowspan="1" colspan="1">14 (7.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;14</td><td align="center" rowspan="1" colspan="1">172 (91.0%)</td><td align="center" rowspan="1" colspan="1">169 (88.9%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg</td><td align="center" rowspan="1" colspan="1">68.8 (8.5&#x02013;117.9; 18.8)</td><td align="center" rowspan="1" colspan="1">68.4 (9.5&#x02013;111.0; 20.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Concomitant illness</td><td align="center" rowspan="1" colspan="1">25 (13.2%)</td><td align="center" rowspan="1" colspan="1">28 (14.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Residing in Manaus urban area</td><td align="center" rowspan="1" colspan="1">170 (89.5%)</td><td align="center" rowspan="1" colspan="1">174 (91.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Temperature (&#x000b0;C)</td><td align="center" rowspan="1" colspan="1">37.2 (34.9&#x02013;40.1; 1.3)</td><td align="center" rowspan="1" colspan="1">37.1 (35.0&#x02013;40.0; 1.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Temperature &#x02265;37.5&#x000b0;C</td><td align="center" rowspan="1" colspan="1">85 (45.0%)</td><td align="center" rowspan="1" colspan="1">77 (40.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Geometric mean parasite density per &#x003bc;L (95% confidence interval)</td><td align="center" rowspan="1" colspan="1">1746 (1475&#x02013;2068)</td><td align="center" rowspan="1" colspan="1">1643 (1412&#x02013;1912)</td></tr><tr><td align="left" rowspan="1" colspan="1">Positive gametocytemia</td><td align="center" rowspan="1" colspan="1">105 (55.6%)</td><td align="center" rowspan="1" colspan="1">114 (60.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (g/dL)</td><td align="center" rowspan="1" colspan="1">13.3 (7.3&#x02013;18.3; 1.9)</td><td align="center" rowspan="1" colspan="1">13.2 (7.8&#x02013;17.3; 1.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Anemia</td><td align="center" rowspan="1" colspan="1">93 (48.9%)</td><td align="center" rowspan="1" colspan="1">83 (43.7%)</td></tr></tbody></table><table-wrap-foot><fn id="fn-01" fn-type="other"><p>Data are expressed as percentage or mean (range; standard deviation), unless specified otherwise.</p></fn></table-wrap-foot></table-wrap><p content-type="indent">Noninferiority was demonstrated (97.5% CI lower bound = 2.74) as genotype-adjusted ACPR rates at day 28 of 100% (165/165) for ASAQ and 93.6% (161/172) for CQ. Although superiority of ASAQ was not demonstrated on day 28 in the ITT population (<italic>P</italic> = .345), it was demonstrated in the PP population and on day 42 for both populations (<xref ref-type="table" rid="T2">Tables 2</xref> and <xref ref-type="table" rid="T3">3</xref>; <xref ref-type="fig" rid="F2">Figure 2</xref>). The difference was larger between day 28 and day 42.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Adequate Clinical and Parasitological Response (ACPR) by Time Point for the Per-Protocol Population</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="center" valign="bottom" rowspan="1" colspan="1">Artesunate&#x02013; Amodiaquine, n = 165 (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Chloroquine, n = 172 (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Difference (95% Confidence Interval)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">
<bold>Day 28</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Genotype-adjusted ACPR</td><td align="center" rowspan="1" colspan="1">165 (100)</td><td align="center" rowspan="1" colspan="1">161 (93.6)</td><td align="center" rowspan="1" colspan="1">6&#x022c5;4% (2&#x022c5;7&#x02013;10&#x022c5;1)</td><td align="center" rowspan="1" colspan="1">&#x022c5;001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total failures</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">11 (6.4)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late clinical failure</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4 (2.3)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late parasitological failure</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">7 (4.1)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="3" rowspan="1">
<italic>Genotype classification of failures</italic>
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Homologous</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">10 (5.8)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Heterologous</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2 (1.2)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Indeterminate</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1 (0&#x022c5;6)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Unadjusted ACPR</td><td align="center" rowspan="1" colspan="1">165 (100.0)</td><td align="center" rowspan="1" colspan="1">159 (92.4)</td><td align="center" rowspan="1" colspan="1">7&#x022c5;6% (3&#x022c5;6&#x02013;11&#x022c5;5)</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x022c5;001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total failures</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">13 (7.5)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late clinical failure</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4 (2.3)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late parasitological failure</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">9 (5.2%</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Day 42</bold>
</td><td align="center" rowspan="1" colspan="1">n = 155</td><td align="center" rowspan="1" colspan="1">n = 166</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Genotype-adjusted ACPR</td><td align="center" rowspan="1" colspan="1">151 (97.4)</td><td align="center" rowspan="1" colspan="1">129 (77.7)</td><td align="center" rowspan="1" colspan="1">19&#x022c5;7% (12&#x022c5;9&#x02013;26&#x022c5;5)</td><td align="center" rowspan="1" colspan="1">&#x0003c;&#x022c5;001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total failures</td><td align="center" rowspan="1" colspan="1">4 (2.6)</td><td align="center" rowspan="1" colspan="1">37 (22.3)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late clinical failure</td><td align="center" rowspan="1" colspan="1">2 (1.3)</td><td align="center" rowspan="1" colspan="1">14 (8.4)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late parasitological failure</td><td align="center" rowspan="1" colspan="1">2 (1.3)</td><td align="center" rowspan="1" colspan="1">23 (13.9)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="5" rowspan="1">
<italic>Genotype classification of failures</italic>
<sup>a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Homologous</td><td align="center" rowspan="1" colspan="1">3(1.9)</td><td align="center" rowspan="1" colspan="1">31 (20.1)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Heterologous</td><td align="center" rowspan="1" colspan="1">2 (1.3)</td><td align="center" rowspan="1" colspan="1">7 (4.2)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Indeterminate polymerase chain reaction</td><td align="center" rowspan="1" colspan="1">1 (0.7)</td><td align="center" rowspan="1" colspan="1">6 (3.6)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Unadjusted ACPR</td><td align="center" rowspan="1" colspan="1">149 (96.1)</td><td align="center" rowspan="1" colspan="1">122 (73.5)</td><td align="center" rowspan="1" colspan="1">22&#x022c5;6% (15&#x022c5;3&#x02013;30&#x022c5;0)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0&#x022c5;001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total failure</td><td align="center" rowspan="1" colspan="1">6 (3.9)</td><td align="center" rowspan="1" colspan="1">44 (36.9)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late clinical failure</td><td align="center" rowspan="1" colspan="1">2 (1.3)</td><td align="center" rowspan="1" colspan="1">17 (10.2)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late parasitological<break/>failure</td><td align="center" rowspan="1" colspan="1">4 (2.6)</td><td align="center" rowspan="1" colspan="1">27 (16.3)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="5" rowspan="1">Parasite and fever clearance</td></tr><tr><td align="left" rowspan="1" colspan="1">Parasite cleared at day 1</td><td align="center" rowspan="1" colspan="1">33 (20.0)</td><td align="center" rowspan="1" colspan="1">4 (2.3)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Parasite cleared at day 2</td><td align="center" rowspan="1" colspan="1">144 (87.3)</td><td align="center" rowspan="1" colspan="1">77 (44.8)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Parasite cleared at day 3</td><td align="center" rowspan="1" colspan="1">164 (99.4)</td><td align="center" rowspan="1" colspan="1">138 (80.2)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Fever cleared at day 1</td><td align="center" rowspan="1" colspan="1">164 (99.4)</td><td align="center" rowspan="1" colspan="1">154 (89.5)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr></tbody></table><table-wrap-foot><fn id="fn-02" fn-type="other"><p>Abbreviation: ACPR, adequate cure and parasitological response.</p></fn><fn id="fn-03" fn-type="other"><p>
<sup>a</sup>Genotyping detailed data available in <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw706/-/DC1">Table Supplementary S1</ext-link>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Efficacy Assessments at Day 28 and Day 42 for the Intention-to-Treat Population</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Variables</th><th align="center" valign="bottom" rowspan="1" colspan="1">Artesunate&#x02013; Amodiaquine, n = 189 (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Chloroquine, n = 190 (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Difference (95% Confidence Interval)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td colspan="5" rowspan="1">
<bold>Day 28</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Genotype-adjusted ACPR</td><td align="center" rowspan="1" colspan="1">177 (93.7)</td><td align="center" rowspan="1" colspan="1">172 (90.5)</td><td align="center" rowspan="1" colspan="1">3.1% (&#x02212;2&#x022c5;3&#x02013;8&#x022c5;5)</td><td align="center" rowspan="1" colspan="1">.345</td></tr><tr><td align="left" rowspan="1" colspan="1">Total failures</td><td align="center" rowspan="1" colspan="1">12 (6.3)</td><td align="center" rowspan="1" colspan="1">18 (9.5)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late clinical failure</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">4 (2.1)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late parasitological failure</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">7 (3.7)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Missing data <sup><bold>a</bold></sup>
</td><td align="center" rowspan="1" colspan="1">12 (6.3)</td><td align="center" rowspan="1" colspan="1">7 (3.7)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="5" rowspan="1">
<italic>Genotype classification of failures</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Homologous</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">10 (5.8)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Heterologous</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2 (1.2)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Indeterminate</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1 (0.6)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Unadjusted ACPR</td><td align="center" rowspan="1" colspan="1">177 (93.7)</td><td align="center" rowspan="1" colspan="1">170 (89.5)</td><td align="center" rowspan="1" colspan="1">4.2% (&#x02212;1.4&#x02013;9.8)</td><td align="center" rowspan="1" colspan="1">.201</td></tr><tr><td align="left" rowspan="1" colspan="1">Total failures<sup>a</sup>
</td><td align="center" rowspan="1" colspan="1">12 (6.3)</td><td align="center" rowspan="1" colspan="1">20 (10.5)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late clinical failure</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4 (2.1)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late parasitological failure</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">9 (4.7)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td colspan="5" rowspan="1">
<bold>Day 42</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Genotype-adjusted ACPR</td><td align="center" rowspan="1" colspan="1">162 (85.7)</td><td align="center" rowspan="1" colspan="1">136 (71.6)</td><td align="center" rowspan="1" colspan="1">14.1% (6.0&#x02013;22.3)</td><td align="center" rowspan="1" colspan="1">.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total failures</td><td align="center" rowspan="1" colspan="1">27 (14.3)</td><td align="center" rowspan="1" colspan="1">54 (28.4)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late clinical failure</td><td align="center" rowspan="1" colspan="1">2 (1.1)</td><td align="center" rowspan="1" colspan="1">15 (7.9)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late parasitological failure</td><td align="center" rowspan="1" colspan="1">2 (1.1)</td><td align="center" rowspan="1" colspan="1">26 (13.7)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Missing data <sup><bold>a</bold></sup>
</td><td align="center" rowspan="1" colspan="1">23 (12.2)</td><td align="center" rowspan="1" colspan="1">13 (6.8)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Genotype classification of failures</italic>
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Homologous</td><td align="center" rowspan="1" colspan="1">3 (1.6)</td><td align="center" rowspan="1" colspan="1">34 (18.4)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Heterologous</td><td align="center" rowspan="1" colspan="1">2 (1.1)</td><td align="center" rowspan="1" colspan="1">7 (3.7)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Indeterminate polymerase chain reaction</td><td align="center" rowspan="1" colspan="1">1 (0.5)</td><td align="center" rowspan="1" colspan="1">7 (3.7)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Unadjusted ACPR</td><td align="center" rowspan="1" colspan="1">160 (84.7)</td><td align="center" rowspan="1" colspan="1">129 (67.9)</td><td align="center" rowspan="1" colspan="1">16.8% (8.4&#x02013;25.2)</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total failures</td><td align="center" rowspan="1" colspan="1">29 (15.5)</td><td align="center" rowspan="1" colspan="1">61 (32.1)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late clinical failure</td><td align="center" rowspan="1" colspan="1">2 (1.1)</td><td align="center" rowspan="1" colspan="1">18 (9.5)</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late parasitological failure</td><td align="center" rowspan="1" colspan="1">4 (2.1)</td><td align="center" rowspan="1" colspan="1">30 (15.8)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Parasite and fever clearance</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Parasite cleared at day 1</td><td align="center" rowspan="1" colspan="1">38 (20.1)</td><td align="center" rowspan="1" colspan="1">9 (4.7)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Parasite cleared at day 2</td><td align="center" rowspan="1" colspan="1">162 (85.7)</td><td align="center" rowspan="1" colspan="1">89 (46.8)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Parasite cleared at day 3</td><td align="center" rowspan="1" colspan="1">184 (97.4)</td><td align="center" rowspan="1" colspan="1">153 (80.5)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Fever cleared at day 1</td><td align="center" rowspan="1" colspan="1">184 (97.4)</td><td align="center" rowspan="1" colspan="1">168 (88.4)</td><td align="center" rowspan="1" colspan="1">
</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr></tbody></table><table-wrap-foot><fn id="fn-04" fn-type="other"><p>Genotyping detailed data available in <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciw706/-/DC1">Supplementary Table S1</ext-link>.</p></fn><fn id="fn-05" fn-type="other"><p>Abbreviation: ACPR, adequate cure and parasitological response.</p></fn><fn id="fn-06" fn-type="other"><p>
<sup><bold>a</bold></sup>Losses to follow-up and samples with genotype assessment..</p></fn></table-wrap-foot></table-wrap><fig fig-type="figure" id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Kaplan-Meier estimates for time to recurrence. <italic>A,</italic> Polymerase chain reaction (PCR)&#x02013;corrected per-protocol (PP) population. <italic>B,</italic> Crude estimate of PP population. <italic>C,</italic> PCR-corrected intention-to-treat (ITT) population. <italic>D,</italic> Crude estimate of ITT population. <italic>P</italic> value from log-rank test. Abbreviations: ASAQ, artesunate&#x02013;amodiaquine; CQ, chloroquine.</p></caption><graphic xlink:href="clinid_ciw706_f0002"/></fig><p content-type="indent">Through genotype classification, 64.8% (34/54) of the CQ arm recurrences (ITT population) were homologous compared with half (3/6) in the ASAQ arm (<xref rid="F3" ref-type="fig">Figure 3A</xref> and <xref rid="T3" ref-type="table">Table 3</xref>). CQ/DCQ blood levels on the day of recurrence were measured for 48 of 54 patients, with 19 being &#x0003e;100 ng/mL, resulting in a CQR prevalence of 11.5% (95% CI, 7.5&#x02013;17.3). This result was further corroborated by both homologous (14/34) and heterologous (5/6) recurrences emerging in the circulation, with CQ/DCQ blood levels as high as 533 ng/mL (<xref rid="F3" ref-type="fig">Figure 3B</xref>).</p><fig fig-type="figure" id="F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>
<italic>A,</italic> Genotype of failures in both arms is shown as same (red diamonds) or distinct (black dots) genotype according to day of follow-up (lines show the median day of failure). <italic>B,</italic> Chloroquine (CQ)/desetylchloroquine blood levels on the day of failure from patients in the CQ arm according to genotype classification (line demarks the 100 ng/mL threshold). Abbreviations: CQ, chloroquine; DCQ, desetylchloroquine; DR: day of reccurrence.</p></caption><graphic xlink:href="clinid_ciw706_f0003"/></fig><p content-type="indent">Parasitemia clearance was faster, and the proportion of patients clearing fever at day 1 was higher for ASAQ (<xref rid="T2" ref-type="table">Tables 2</xref> and <xref rid="T3" ref-type="table">3</xref>). From day 7, 2.4% of patients treated with ASAQ and 14.7% in the CQ group presented with microscopically detected gametocytes during follow-up (<italic>P</italic> &#x0003c; .001). The GEE model demonstrated a lower overall gametocyte-positive density in the ASAQ arm compared with that of CQ (4.7 vs 12.2 gametocyte-positive slides/100 person-weeks, respectively; <italic>P</italic> &#x0003c; .001). Risk of developing gametocytemia after treatment initiation in patients with no gametocytes at inclusion (ASAQ, n = 83; CQ, n = 76) was higher for CQ (20.2% vs 55.4%; <italic>P</italic> &#x0003c; 0&#x000b7;001). There was no association between delayed parasite clearance and risk of recurrence (odds ratio = 1.1; 95% CI, 0.7&#x02013;1.6; <italic>P</italic> = .836) in the CQ arm.</p><p content-type="indent">There was a relative decrease of hemoglobin (Hb) between inclusion and day 7 for all patients (&#x02212;2.5; standard deviation = 8.4), with greater reduction observed for ASAQ (&#x02212;4.2 [7.4] vs &#x02212;0.9 [9.0]; <italic>P</italic> &#x0003c; .001). There was a similar proportion of patients who presented with grade 2 or higher anemia at day 7 (3 [1.6%] vs 2 [1.1%]). At day 28, patients who received CQ presented with a higher increase from baseline (0.3 [13.2] vs 3.7 [12.0]; <italic>P</italic> = .005). Overall AE rates were similar (<xref ref-type="table" rid="T4">Table 4</xref>). Severe AEs were only observed in the ASAQ arm, none with sequelae.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Most Frequent Adverse Events Reported in the Safety Population</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Variables</th><th align="center" valign="bottom" rowspan="1" colspan="1">Artesunate&#x02013; Amodiaquine, n = 190 (%)<sup>a</sup>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Chloroquine, n = 190 (%)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">All AEs</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients with at least 1 event</td><td align="center" rowspan="1" colspan="1">79 (41.6)</td><td align="center" rowspan="1" colspan="1">85 (44.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac disorders</td><td align="center" rowspan="1" colspan="1">35 (18.4)</td><td align="center" rowspan="1" colspan="1">21 (11.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin disorders</td><td align="center" rowspan="1" colspan="1">14 (7.4)</td><td align="center" rowspan="1" colspan="1">23 (12.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Infections and infestations</td><td align="center" rowspan="1" colspan="1">16 (8.4)</td><td align="center" rowspan="1" colspan="1">21 (11.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastrointestinal disorders</td><td align="center" rowspan="1" colspan="1">16 (8.4)</td><td align="center" rowspan="1" colspan="1">15 (7.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Psychiatric disorders/insomnia</td><td align="center" rowspan="1" colspan="1">8 (4.2)</td><td align="center" rowspan="1" colspan="1">12 (6.3)</td></tr><tr><td colspan="3" rowspan="1">Drug-related AEs<sup>b</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients with at least 1 of the following:</td><td align="center" rowspan="1" colspan="1">59 (31.1)</td><td align="center" rowspan="1" colspan="1">47 (14.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sinus bradycardia</td><td align="center" rowspan="1" colspan="1">28 (14.7)</td><td align="center" rowspan="1" colspan="1">11 (5.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pruritus</td><td align="center" rowspan="1" colspan="1">13 (6.8)</td><td align="center" rowspan="1" colspan="1">19 (10.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">Increased ALAT</td><td align="center" rowspan="1" colspan="1">9 (4.7)</td><td align="center" rowspan="1" colspan="1">8 (4.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastritis</td><td align="center" rowspan="1" colspan="1">8 (4.2)</td><td align="center" rowspan="1" colspan="1">5 (2.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="center" rowspan="1" colspan="1">6 (3.2)</td><td align="center" rowspan="1" colspan="1">5 (2.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Insomnia</td><td align="center" rowspan="1" colspan="1">2 (1.1)</td><td align="center" rowspan="1" colspan="1">4 (2.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea</td><td align="center" rowspan="1" colspan="1">2 (1.1)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">At least 1 event of special interest</td><td align="center" rowspan="1" colspan="1">8 (4.2)</td><td align="center" rowspan="1" colspan="1">9 (4.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Increased ALAT<sup>c</sup>
</td><td align="center" rowspan="1" colspan="1">8 (4.2)</td><td align="center" rowspan="1" colspan="1">8 (4.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutropenia<sup>d</sup>
</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td colspan="3" rowspan="1">Serious AEs&#x000b6;</td></tr><tr><td align="left" rowspan="1" colspan="1">Patients presenting at least 1 serious AE*</td><td align="center" rowspan="1" colspan="1">3 (1.6)</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe gastritis</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Extrapyramidal syndrome</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="fn-07" fn-type="other"><p>Only AEs that affected at least 4% in each group are listed.</p></fn><fn id="fn-08" fn-type="other"><p>Abbreviations: AE, adverse event; ALAT, alanine aminotransferase.</p></fn><fn id="fn-09" fn-type="other"><p>
<sup><bold>a</bold></sup> The patient with mixed infection detected by polymerase chain reaction was included in the safety analyses.</p></fn><fn id="fn-10" fn-type="other"><p>
<sup>b</sup> Only events that affected at least 1% of the population in each group are listed.</p></fn><fn id="fn-11" fn-type="other"><p>
<sup>c</sup> ALAT &#x0003e;5 &#x000d7; upper limit of normal (ULN) value, or ALAT &#x0003e;3 &#x000d7; ULN if ALAT was &#x0003e;ULN on day 0, or ALAT &#x0003e;3 &#x000d7; ULN associated with total bilirubin &#x0003e;2&#x000d7;ULN.</p></fn><fn id="fn-12" fn-type="other"><p>
<sup>d</sup> Neutrophil count &#x0003c;400/mm<sup>3</sup> in children aged 3 months to 12 years or &#x0003c;750/mm<sup>3</sup> in children aged &#x0003e;12 years or adults. <sup>&#x000b6;</sup>Events were classified as serious AEs based on the need for intravenous medication to alleviate the symptoms.</p></fn><fn id="fn-13" fn-type="other"><p>*There were no investigational product discontinuation or deaths in the study. Full recovery occurred for all AEs.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s9"><title>DISCUSSION</title><p>We observed high efficacy of the ASAQ FDC against CQ-resistant <italic>P. vivax</italic> with respect to ACPR and other efficacy outcomes. This is the first study to compare the ASAQ combination with chloroquine against <italic>P. vivax</italic> infection and the first trial to compare an ACT with CQ in Latin America [<xref rid="CIT0001" ref-type="bibr">1</xref>].</p><p content-type="indent">A remarkable result of this study is the high efficacy of ASAQ at day 42 (for which all recurrences occurred after day 40). Interpretation of failures occurring after day 28 is complicated by the possibility of recurrences being relapses or reinfections [<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0025" ref-type="bibr">25</xref>]. Despite this caveat, we believe the observed late recurrences indicate the existence of low-grade resistance to CQ, which would suppress but not completely eliminate circulating parasites [<xref rid="CIT0012" ref-type="bibr">12</xref>]. This is based on 2 important assumptions: very low risk of reinfection, as most patients (90.5%) resided in urban areas with no active malaria transmission [<xref rid="CIT0023" ref-type="bibr">23</xref>], and negligible contribution of relapses, which usually occur after day 35 in the region [<xref rid="CIT0032" ref-type="bibr">32</xref>, <xref rid="CIT0045" ref-type="bibr">45</xref>, <xref rid="CIT0046" ref-type="bibr">46</xref>].</p><p content-type="indent">In the absence of PQ administration, the drug&#x02019;s elimination half-life is an important property to be considered against <italic>P. vivax</italic> due to the post-treatment prophylactic effect [<xref rid="CIT0009" ref-type="bibr">9</xref>]. Its influence is illustrated by 2 trials that compared the ASAQ loose-dose combination to dihydroartemisinin&#x02013;piperaquine, an ACT with a longer half-life. Lower efficacy against late recurrences of ASAQ [<xref rid="CIT0043" ref-type="bibr">43</xref>] was not confirmed when PQ was coadministered [<xref rid="CIT0044" ref-type="bibr">44</xref>]. This rationale is supported by the higher efficacy of CQ in preventing late recurrences compared with drugs with shorter half-lives (arthemeter&#x02013;lumefantrine) in areas of low prevalence of CQR [<xref rid="CIT0047" ref-type="bibr">47</xref>]. Thus, our results provide strong evidence of a higher-than-expected CQR prevalence because, even though CQ and its metabolites&#x02019; half-lives are longer, there was a large number of recurrences in the CQ arm.</p><p content-type="indent">The genotype-adjusted ACPR rates were measured in an attempt to gain a more rigorous case definition of CQR. Genotyping has been applied in <italic>P. vivax</italic> efficacy studies with interesting results [<xref rid="CIT0035" ref-type="bibr">35</xref>, <xref rid="CIT0036" ref-type="bibr">36</xref>]. However, unlike in <italic>P. falciparum</italic>, there are no well-defined criteria to differentiate recrudescence from reinfection and relapse [<xref rid="CIT0025" ref-type="bibr">25</xref>]. PCR correction will not necessarily lead to more precise estimation of efficacy in areas of low endemicity, where homologous hypnozoites are more likely [<xref rid="CIT0034" ref-type="bibr">34</xref>].</p><p content-type="indent">ASAQ was more effective in clearing patent gametocytemia. CQ may take up to 4 days for gametocyte clearance [<xref rid="CIT0048" ref-type="bibr">48</xref>]. Studies have found an association between prolonged gametocytemia and asexual stage recurrence [<xref rid="CIT0049" ref-type="bibr">49</xref>]. It is not clear if use of an ACT has an effect on reducing transmission.</p><p content-type="indent">Hb reduction at day 7 was higher in patients who received ASAQ. Possible explanations include higher inflammatory response and/or oxidative stress associated with treatment, suppression of the blood marrow by artesunate, and pitting [<xref rid="CIT0050" ref-type="bibr">50</xref>, <xref rid="CIT0051" ref-type="bibr">51</xref>]. The risk of severe anemia after ACT is considered low [<xref rid="CIT0052" ref-type="bibr">52</xref>]; indeed, there was no severe anemia in our study.</p><p content-type="indent">The safety and tolerability of ASAQ FDC were consistent with what was found in previous studies that used this combination in the approved indication &#x0201c;treatment of uncomplicated <italic>P. falciparum</italic> malaria&#x0201d; [<xref rid="CIT0042" ref-type="bibr">42</xref>]. Sinus bradycardia occurred without symptoms or clinical complications, and there was no difference regarding the corrected QT inverval (QTc).</p><p content-type="indent">A limitation of our study was the small number of children included. This population is at higher risk of treatment failure [<xref rid="CIT0053" ref-type="bibr">53</xref>, <xref rid="CIT0054" ref-type="bibr">54</xref>], for which age-stratified sampling would be important. There was a higher loss to follow-up in the ASAQ arm, which had an impact on the efficacy assessment in the ITT population. An examination of the notification database did not reveal a higher rate of failure among losses. As we were not able to assess the pharmacokinetic profile of amodiaquine, evaluation of the effect of a longer elimination half-life in this population on efficacy against late recurrences was not possible.</p><p content-type="indent">By not coadministering PQ, we were able to estimate CQR, which at 11.5%, considering concurrent blood drug levels criterion, is very high. This is important, as patients receiving CQ are at higher risk of recurring episodes from resistant parasites that arise from either recrudescence or relapse. These findings also suggest that the usual methods for measuring CQ efficacy are prone to underestimate the true CQR rates. Most studies of <italic>P. vivax</italic> efficacy restrict follow-up to 28 days in order to minimize the contribution of relapses, considering CQ elimination half-life. We believe this can result in underestimation of resistance, which, in our study, could be as high as 30% based on the risk difference against an efficacious comparator. This difference highlights the need to develop better designs and strategies for measuring antimalarial efficacy against <italic>P. vivax</italic>.</p></sec><sec id="s10"><title>CONCLUSIONS</title><p>This is the first trial to compare an ACT with CQ as blood schizontocidal against <italic>P. vivax</italic> in Latin America. We demonstrated that CQR is underestimated in the region and that a change in treatment policy should be considered. Recently <italic>Plasmodium vivax</italic> has received increased attention, requiring development of new strategies and tools [<xref rid="CIT0055" ref-type="bibr">55</xref>]. The choice of an effective schizontocidal drug, therefore, cannot be underestimated. Although CQ is still the first-line therapy in most endemic countries, resistance is a growing problem, probably underestimated because of coadministration with PQ and misclassification of recrudescence as relapse. The decision to substitute CQ for an ACT as the drug of choice for treating <italic>P. vivax</italic> infections is complex and should be based on different factors, including the prevalence of CQ-resistant parasites; the current treatment adopted for <italic>P. falciparum</italic>; efficacy of the partner drug; interaction of the ACT with PQ; and the potential impact of reducing transmission [<xref rid="CIT0013" ref-type="bibr">13</xref>]. In order to establish unified treatment recommendations for <italic>P. falciparum</italic> and <italic>P. vivax</italic>, it is necessary to provide a more effective option and reduce the risk of treating <italic>P. falciparum</italic> with CQ due to misdiagnosis [<xref rid="CIT0050" ref-type="bibr">50</xref>]. We believe that CQ should be replaced by a more efficacious alternative in this region and expect policymakers to consider these findings in order to define the best strategies to accelerate the path toward malaria eradication.</p></sec><sec><title>Supplementary Data</title><p>Supplementary materials are available at <italic>Clinical Infectious Diseases</italic> online. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.</p></sec><sec><title>Notes</title><p>
<bold><italic>Funding</italic></bold>. This study was funded by Sanofi. The study sponsor participated in the development the protocol, interpreted the data, helped write the report, and performed monitoring.</p><p>
<bold><italic>Acknowledgements</italic></bold>. We acknowledge Director-President of FMT-HVD Professor Maria Alecrim for the institutional support, all the personnel from the Malaria Laboratory for their contribution in running the trial, and the study monitor from Sanofi. We thank the patients and their families for taking part in the study. C. T. D. R. and M. V. G. L. are recipients of a grant from the Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico as <italic>Bolsistas de Produtividade</italic> and A. M. S. receives a short-term training grant from WHO&#x02019;s Special Programme for Research and Training in Tropical Diseases.</p><p>
<bold><italic>Author contributions</italic></bold>. A. M. S., V. L., C. D. T. R., and M. V. G. L. designed and coordinated the study. A. M. S., A. C. A., B. L. M., K. M., M. M. M., and M. C. M. participated in data collection. G. C. M., A. K., M. M. M., I. F., and J. L. F. V. participated in the laboratory analyses. A. M. S., V. L., and M. V. G. L. conducted the statistical analyses. A. M. S. wrote the first draft of the manuscript. All authors participated in data interpretation and approved the final version and take responsibility for accuracy and completeness of data reporting and for the decision to submit for publication.</p><p>
<bold><italic>Potential conflicts of interest</italic></bold>. V. L. is employed by Sanofi. All other authors report no conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_64_2_166__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_ciw706_Supp_table_1_v2.docx"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_ciw706_Supplement_Text_1.docx"/>
</supplementary-material>
</sec>
</body><back><ref-list><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="book">
<collab>World Health Organization</collab>. <source><italic>World Malaria Report 2015</italic></source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <year>2015</year>.</mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gething</surname><given-names>PW</given-names></name><name name-style="western"><surname>Elyazar</surname><given-names>IR</given-names></name><name name-style="western"><surname>Moyes</surname><given-names>CL</given-names></name><etal/></person-group>
<article-title>A long neglected world malaria map: <italic>Plasmodium vivax</italic> endemicity in 2010</article-title>. <source>PLoS Negl Trop Dis</source>
<year>2012</year>; <volume>6</volume>: <fpage>e1814</fpage>.<pub-id pub-id-type="pmid">22970336</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Douglas</surname><given-names>NM</given-names></name><name name-style="western"><surname>Pontororing</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Lampah</surname><given-names>DA</given-names></name><etal/></person-group>
<article-title>Mortality attributable to <italic>Plasmodium vivax</italic> malaria: a clinical audit from Papua, Indonesia</article-title>. <source>BMC Med</source>
<year>2014</year>; <volume>12</volume>:<fpage>217</fpage>.<pub-id pub-id-type="pmid">25406857</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Siqueira</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lacerda</surname><given-names>MV</given-names></name><name name-style="western"><surname>Magalh&#x000e3;es</surname><given-names>BM</given-names></name><etal/></person-group>
<article-title>Characterization of <italic>Plasmodium vivax</italic>-associated admissions to reference hospitals in Brazil and India</article-title>. <source>BMC Med</source>
<year>2015</year>; <volume>13</volume>:<fpage>57</fpage>.<pub-id pub-id-type="pmid">25889040</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name></person-group>
<article-title>Pernicious and threatening <italic>Plasmodium vivax</italic> as reality</article-title>. <source>Am J Trop Med Hyg</source>
<year>2014</year>; <volume>91</volume>:<fpage>1</fpage>&#x02013;<lpage>2</lpage>.<pub-id pub-id-type="pmid">24752684</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal">
<collab>The malERA Consultative Group on Drugs</collab>. <article-title>A research agenda for malaria eradication: drugs</article-title>. <source>PLoS Med</source>
<year>2011</year>; <volume>8</volume>: <fpage>e1000402</fpage>.<pub-id pub-id-type="pmid">21311580</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Plowe</surname><given-names>CV</given-names></name></person-group>
<article-title>The evolution of drug-resistant malaria</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<year>2009</year>; <volume>103</volume>(<issue>Suppl 1</issue>):<fpage>S11</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">19084883</pub-id></mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="book">
8.<collab>World Health Organization</collab>. <source><italic>Guidelines for the Treatment of Malaria</italic></source>. <edition>2nd ed</edition>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>, <year>2010</year>:xi, <fpage>194</fpage> p.</mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Maguire</surname><given-names>JD</given-names></name><name name-style="western"><surname>Price</surname><given-names>RN</given-names></name></person-group>
<article-title>Diagnosis and treatment of <italic>Plasmodium vivax</italic> malaria</article-title>. <source>Adv Parasitol</source>
<year>2012</year>; <volume>80</volume>:<fpage>203</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">23199489</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name></person-group>
<article-title>Resistance to therapies for infection by <italic>Plasmodium vivax</italic>
</article-title>. <source>Clin Microbiol Rev</source>
<year>2009</year>; <volume>22</volume>:<fpage>508</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">19597012</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gon&#x000e7;alves</surname><given-names>LA</given-names></name><name name-style="western"><surname>Cravo</surname><given-names>P</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>MU</given-names></name></person-group>
<article-title>Emerging <italic>Plasmodium vivax</italic> resistance to chloroquine in South America: an overview</article-title>. <source>Memorias do Instituto Oswaldo Cruz</source>
<year>2014</year>; 0(ahead): 0-.</mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>RN</given-names></name><name name-style="western"><surname>von Seidlein</surname><given-names>L</given-names></name><name name-style="western"><surname>Valecha</surname><given-names>N</given-names></name><name name-style="western"><surname>Nosten</surname><given-names>F</given-names></name><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group>
<article-title>Global extent of chloroquine-resistant <italic>Plasmodium vivax</italic>: a systematic review and meta-analysis</article-title>. <source>Lancet Infect Dis</source>
<year>2014</year>; <volume>14</volume>:<fpage>982</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">25213732</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>RN</given-names></name><name name-style="western"><surname>Douglas</surname><given-names>NM</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>NM</given-names></name><name name-style="western"><surname>von Seidlein</surname><given-names>L</given-names></name></person-group>
<article-title>
<italic>Plasmodium vivax</italic> treatments: what are we looking for?</article-title>
<source>Curr Opin Infect Dis</source>
<year>2011</year>; <volume>24</volume>:<fpage>578</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">21986614</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name><name name-style="western"><surname>Sustriayu Nalim</surname><given-names>MF</given-names></name><name name-style="western"><surname>Basri</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Survey of resistance to chloroquine by <italic>Plasmodium vivax</italic> in Indonesia</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<year>1996</year>; <volume>90</volume>:<fpage>409</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">8882190</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Guthmann</surname><given-names>JP</given-names></name><name name-style="western"><surname>Pittet</surname><given-names>A</given-names></name><name name-style="western"><surname>Lesage</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>
<italic>Plasmodium vivax</italic> resistance to chloroquine in Dawei, southern Myanmar</article-title>. <source>Trop Med Int Health</source>
<year>2008</year>; <volume>13</volume>:<fpage>91</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18291007</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gogtay</surname><given-names>N</given-names></name><name name-style="western"><surname>Kannan</surname><given-names>S</given-names></name><name name-style="western"><surname>Thatte</surname><given-names>UM</given-names></name><name name-style="western"><surname>Olliaro</surname><given-names>PL</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>D</given-names></name></person-group>
<article-title>Artemisinin-based combination therapy for treating uncomplicated <italic>Plasmodium vivax</italic> malaria</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2013</year>; <volume>10</volume>:<fpage>CD008492</fpage>.</mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>de Santana Filho</surname><given-names>FS</given-names></name><name name-style="western"><surname>Arcanjo</surname><given-names>AR</given-names></name><name name-style="western"><surname>Chehuan</surname><given-names>YM</given-names></name><etal/></person-group>
<article-title>Chloroquine-resistant <italic>Plasmodium vivax</italic>, Brazilian Amazon</article-title>. <source>Emerg Infect Dis</source>
<year>2007</year>; <volume>13</volume>:<fpage>1125</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">18214203</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Soto</surname><given-names>J</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>J</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>
<italic>Plasmodium vivax</italic> clinically resistant to chloroquine in Colombia</article-title>. <source>Am J Trop Med Hyg</source>
<year>2001</year>; <volume>65</volume>:<fpage>90</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">11508397</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ruebush</surname><given-names>TK</given-names><suffix>II</suffix></name><name name-style="western"><surname>Zegarra</surname><given-names>J</given-names></name><name name-style="western"><surname>Cairo</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Chloroquine-resistant <italic>Plasmodium vivax</italic> malaria in Peru</article-title>. <source>Am J Trop Med Hyg</source>
<year>2003</year>; <volume>69</volume>:<fpage>548</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">14695094</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Keystone</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kain</surname><given-names>KC</given-names></name></person-group>
<article-title>Failure of combined chloroquine and high-dose primaquine therapy for <italic>Plasmodium vivax</italic> malaria acquired in Guyana, South America</article-title>. <source>Clin Infect Dis</source>
<year>1996</year>; <volume>23</volume>:<fpage>1171</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">8922821</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kauss</surname><given-names>T</given-names></name><name name-style="western"><surname>Fawaz</surname><given-names>F</given-names></name><name name-style="western"><surname>Guyot</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Fixed artesunate-amodiaquine combined pre-formulation study for the treatment of malaria</article-title>. <source>Int J Pharm</source>
<year>2010</year>; <volume>395</volume>:<fpage>198</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">20635516</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lacaze</surname><given-names>C</given-names></name><name name-style="western"><surname>Kauss</surname><given-names>T</given-names></name><name name-style="western"><surname>Kiechel</surname><given-names>JR</given-names></name><etal/></person-group>
<article-title>The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership</article-title>. <source>Malar J</source>
<year>2011</year>; <volume>10</volume>:<fpage>142</fpage>.<pub-id pub-id-type="pmid">21605361</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sampaio</surname><given-names>VS</given-names></name><name name-style="western"><surname>Siqueira</surname><given-names>AM</given-names></name><name name-style="western"><surname>Alecrim</surname><given-names>Md</given-names></name><etal/></person-group>
<article-title>Malaria in the State of Amazonas: a typical Brazilian tropical disease influenced by waves of economic development</article-title>. <source>Rev Soc Bras Med Trop</source>
<year>2015</year>; <volume>48</volume>(<issue>Suppl 1</issue>):<fpage>4</fpage>&#x02013;<lpage>11</lpage>.</mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="book">
<collab>Brasil. Minist&#x000e9;rio da Sa&#x000fa;de</collab>. <source><italic>Guia Pr&#x000e1;tico de Tratamento da Mal&#x000e1;ria no Brasil</italic></source>. <publisher-loc>Bras&#x000ed;lia, Brasil</publisher-loc>: <publisher-name>Ministerio da Sa&#x000fa;de</publisher-name>, <year>2010</year>.</mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="book">
<collab>MMV, WHO</collab>. <source>Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations: informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization, 29&#x02013;31 May 2007, Amsterdam, The Netherlands</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <year>2008</year>.</mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="book">
<collab>WHO</collab>. <source><italic>Methods for Surveillance of Antimalarial Drug Efficacy</italic></source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <year>2009</year>.</mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dua</surname><given-names>VK</given-names></name><name name-style="western"><surname>Kar</surname><given-names>PK</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>NC</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>VP</given-names></name></person-group>
<article-title>Determination of chloroquine and desethylchloroquine in plasma and blood cells of <italic>Plasmodium vivax</italic> malaria cases using liquid chromatography</article-title>. <source>J Pharm Biomed Anal</source>
<year>1999</year>; <volume>21</volume>:<fpage>199</fpage>&#x02013;<lpage>205</lpage>.<pub-id pub-id-type="pmid">10701928</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name><name name-style="western"><surname>Leksana</surname><given-names>B</given-names></name><name name-style="western"><surname>Masbar</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Diagnosis of resistance to chloroquine by <italic>Plasmodium vivax</italic>: timing of recurrence and whole blood chloroquine levels</article-title>. <source>Am J Trop Med Hyg</source>
<year>1997</year>; <volume>56</volume>:<fpage>621</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">9230792</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="book">
<collab>World Health Organization</collab>. <source><italic>Basic Malaria Microscopy</italic></source>. <edition>2nd ed</edition>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <year>2010</year>.</mixed-citation></ref><ref id="CIT0030"><label>30.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Snounou</surname><given-names>G</given-names></name><name name-style="western"><surname>Viriyakosol</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>XP</given-names></name><etal/></person-group>
<article-title>High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction</article-title>. <source>Mol Biochem Parasitol</source>
<year>1993</year>; <volume>61</volume>:<fpage>315</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">8264734</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mar&#x000ed;n-Men&#x000e9;ndez</surname><given-names>A</given-names></name><name name-style="western"><surname>Bardaj&#x000ed;</surname><given-names>A</given-names></name><name name-style="western"><surname>Mart&#x000ed;nez-Espinosa</surname><given-names>FE</given-names></name><etal/></person-group>
<article-title>Rosetting in <italic>Plasmodium vivax</italic>: a cytoadhesion phenotype associated with anaemia</article-title>. <source>PLoS Negl Trop Dis</source>
<year>2013</year>; <volume>7</volume>:<fpage>e2155</fpage>.<pub-id pub-id-type="pmid">23593522</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>de Araujo</surname><given-names>FC</given-names></name><name name-style="western"><surname>de Rezende</surname><given-names>AM</given-names></name><name name-style="western"><surname>Fontes</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>LH</given-names></name><name name-style="western"><surname>Alves de Brito</surname><given-names>CF</given-names></name></person-group>
<article-title>Multiple-clone activation of hypnozoites is the leading cause of relapse in <italic>Plasmodium vivax</italic> infection</article-title>. <source>PLoS One</source>
<year>2012</year>; <volume>7</volume>:<fpage>e49871</fpage>.<pub-id pub-id-type="pmid">23185469</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Orjuela-S&#x000e1;nchez</surname><given-names>P</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>NS</given-names></name><name name-style="western"><surname>da Silva-Nunes</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>MU</given-names></name></person-group>
<article-title>Recurrent parasitemias and population dynamics of <italic>Plasmodium vivax</italic> polymorphisms in rural Amazonia</article-title>. <source>Am J Trop Med Hyg</source>
<year>2009</year>; <volume>81</volume>:<fpage>961</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">19996423</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>HP</given-names></name><name name-style="western"><surname>Wampfler</surname><given-names>R</given-names></name><name name-style="western"><surname>Carter</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Estimation of the antirelapse efficacy of tafenoquine, using <italic>Plasmodium vivax</italic> genotyping</article-title>. <source>J Infect Dis</source>
<year>2016</year>; <volume>213</volume>:<fpage>794</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">26500351</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Barnadas</surname><given-names>C</given-names></name><name name-style="western"><surname>Koepfli</surname><given-names>C</given-names></name><name name-style="western"><surname>Karunajeewa</surname><given-names>HA</given-names></name><name name-style="western"><surname>Siba</surname><given-names>PM</given-names></name><name name-style="western"><surname>Davis</surname><given-names>TM</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>I</given-names></name></person-group>
<article-title>Characterization of treatment failure in efficacy trials of drugs against <italic>Plasmodium vivax</italic> by genotyping neutral and drug resistance-associated markers</article-title>. <source>Antimicrob Agents Chemother</source>
<year>2011</year>; <volume>55</volume>:<fpage>4479</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">21709097</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Koepfli</surname><given-names>C</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>I</given-names></name><name name-style="western"><surname>Marfurt</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Evaluation of <italic>Plasmodium vivax</italic> genotyping markers for molecular monitoring in clinical trials</article-title>. <source>J Infect Dis</source>
<year>2009</year>; <volume>199</volume>:<fpage>1074</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">19275476</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ndiaye</surname><given-names>JL</given-names></name><name name-style="western"><surname>Randrianarivelojosia</surname><given-names>M</given-names></name><name name-style="western"><surname>Sagara</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Randomized, multicentre assessment of the efficacy and safety of ASAQ&#x02013;a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated <italic>Plasmodium falciparum</italic> malaria</article-title>. <source>Malar J</source>
<year>2009</year>; <volume>8</volume>:<fpage>125</fpage>.<pub-id pub-id-type="pmid">19505304</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Fleiss</surname><given-names>JL</given-names></name><name name-style="western"><surname>Levin</surname><given-names>B</given-names></name><name name-style="western"><surname>Paik</surname><given-names>MC</given-names></name></person-group>
<source><italic>Statistical Methods for Rates and Proportions</italic></source>: <publisher-name>John Wiley &#x00026; Sons</publisher-name>, <year>2013</year>.</mixed-citation></ref><ref id="CIT0039"><label>39.</label><mixed-citation publication-type="journal">
<collab>Committee for Proprietary Medicinal P</collab>. <article-title>Points to consider on switching between superiority and non-inferiority</article-title>. <source>Br J Clin Pharmacol</source>
<year>2001</year>; <volume>52</volume>:<fpage>223</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">11560553</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hanley</surname><given-names>JA</given-names></name><name name-style="western"><surname>Negassa</surname><given-names>A</given-names></name><name name-style="western"><surname>Edwardes</surname><given-names>MD</given-names></name><name name-style="western"><surname>Forrester</surname><given-names>JE</given-names></name></person-group>
<article-title>Statistical analysis of correlated data using generalized estimating equations: an orientation</article-title>. <source>Am J Epidemiol</source>
<year>2003</year>; <volume>157</volume>:<fpage>364</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">12578807</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41.</label><mixed-citation publication-type="other">
<collab>WHO</collab>. <comment>Haemoglobin concentration for the diagnosis of anaemia and assessment of severity</comment> Available at: <uri xlink:href="http://www.who.int/vmnis/indicators/haemoglobin/en/">http://www.who.int/vmnis/indicators/haemoglobin/en/</uri>.</mixed-citation></ref><ref id="CIT0042"><label>42.</label><mixed-citation publication-type="journal">
<collab>WorldWide Antimalarial Resistance Network ASAQSG</collab>. <article-title>The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data</article-title>. <source>BMC Med</source>
<year>2015</year>; <volume>13</volume>:<fpage>66</fpage>.<pub-id pub-id-type="pmid">25888957</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hasugian</surname><given-names>AR</given-names></name><name name-style="western"><surname>Purba</surname><given-names>HL</given-names></name><name name-style="western"><surname>Kenangalem</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant <italic>Plasmodium falciparum</italic> and <italic>Plasmodium vivax</italic> malaria</article-title>. <source>Clin Infect Dis</source>
<year>2007</year>; <volume>44</volume>:<fpage>1067</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">17366451</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pasaribu</surname><given-names>AP</given-names></name><name name-style="western"><surname>Chokejindachai</surname><given-names>W</given-names></name><name name-style="western"><surname>Sirivichayakul</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia</article-title>. <source>J Infect Dis</source>
<year>2013</year>; <volume>208</volume>:<fpage>1906</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">23926329</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Battle</surname><given-names>KE</given-names></name><name name-style="western"><surname>Karhunen</surname><given-names>MS</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Geographical variation in <italic>Plasmodium vivax</italic> relapse</article-title>. <source>Malar J</source>
<year>2014</year>; <volume>13</volume>:<fpage>144</fpage>.<pub-id pub-id-type="pmid">24731298</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sim&#x000f5;es</surname><given-names>LR</given-names></name><name name-style="western"><surname>Alves</surname><given-names>ER</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Ribatski-Silva</surname><given-names>D</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>LT</given-names></name><name name-style="western"><surname>Nery</surname><given-names>AF</given-names></name><name name-style="western"><surname>Fontes</surname><given-names>CJF</given-names></name></person-group>
<article-title>Factors associated with recurrent <italic>Plasmodium vivax</italic> malaria in Porto Velho, Rondonia State, Brazil, 2009</article-title>. <source>Cad Saude Publica</source>
<year>2014</year>; <volume>30</volume>:<fpage>1403</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">25166938</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>J</given-names></name><name name-style="western"><surname>Alemayehu</surname><given-names>BH</given-names></name><name name-style="western"><surname>Reithinger</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>In vivo efficacy of artemether-lumefantrine and chloroquine against <italic>Plasmodium vivax</italic>: a randomized open label trial in central Ethiopia</article-title>. <source>PLoS One</source>
<year>2013</year>; <volume>8</volume>:<fpage>e63433</fpage>.<pub-id pub-id-type="pmid">23717423</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jeffery</surname><given-names>GM</given-names></name></person-group>
<article-title>Infectivity to mosquitoes of <italic>Plasmodium vivax</italic> following treatment with chloroquine and other antimalarials</article-title>. <source>Am J Trop Med Hyg</source>
<year>1958</year>; <volume>7</volume>:<fpage>207</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">13533726</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pukrittayakamee</surname><given-names>S</given-names></name><name name-style="western"><surname>Imwong</surname><given-names>M</given-names></name><name name-style="western"><surname>Singhasivanon</surname><given-names>P</given-names></name><name name-style="western"><surname>Stepniewska</surname><given-names>K</given-names></name><name name-style="western"><surname>Day</surname><given-names>NJ</given-names></name><name name-style="western"><surname>White</surname><given-names>NJ</given-names></name></person-group>
<article-title>Effects of different antimalarial drugs on gametocyte carriage in <italic>P. vivax</italic> malaria</article-title>. <source>Am J Trop Med Hyg</source>
<year>2008</year>; <volume>79</volume>:<fpage>378</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">18784229</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Douglas</surname><given-names>NM</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>NM</given-names></name><name name-style="western"><surname>Angus</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Nosten</surname><given-names>F</given-names></name><name name-style="western"><surname>Price</surname><given-names>RN</given-names></name></person-group>
<article-title>Artemisinin combination therapy for vivax malaria</article-title>. <source>Lancet Infect Dis</source>
<year>2010</year>; <volume>10</volume>:<fpage>405</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">20510281</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Douglas</surname><given-names>NM</given-names></name><name name-style="western"><surname>Anstey</surname><given-names>NM</given-names></name><name name-style="western"><surname>Buffet</surname><given-names>PA</given-names></name><etal/></person-group>
<article-title>The anaemia of <italic>Plasmodium vivax</italic> malaria</article-title>. <source>Malar J</source>
<year>2012</year>; <volume>11</volume>:<fpage>135</fpage>.<pub-id pub-id-type="pmid">22540175</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sagara</surname><given-names>I</given-names></name><name name-style="western"><surname>Piarroux</surname><given-names>R</given-names></name><name name-style="western"><surname>Djimde</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Delayed anemia assessment in patients treated with oral artemisinin derivatives for uncomplicated malaria: a pooled analysis of clinical trials data from Mali</article-title>. <source>Malar J</source>
<year>2014</year>; <volume>13</volume>:<fpage>358</fpage>.<pub-id pub-id-type="pmid">25217396</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Siqueira</surname><given-names>AM</given-names></name><name name-style="western"><surname>Coutinho</surname><given-names>LI</given-names></name><name name-style="western"><surname>Gurgel</surname><given-names>RL</given-names></name><etal/></person-group>
<article-title>Slow clearance of <italic>Plasmodium vivax</italic> with chloroquine amongst children below six months of age in the Brazilian Amazon</article-title>. <source>Memorias do Instituto Oswaldo Cruz</source>
<year>2014</year>; <volume>109</volume>:<fpage>540</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">25099334</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ursing</surname><given-names>J</given-names></name><name name-style="western"><surname>Eksborg</surname><given-names>S</given-names></name><name name-style="western"><surname>Rombo</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Chloroquine is grossly under dosed in young children with malaria: implications for drug resistance</article-title>. <source>PLoS One</source>
<year>2014</year>; <volume>9</volume>:<fpage>e86801</fpage>.<pub-id pub-id-type="pmid">24466245</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>I</given-names></name><name name-style="western"><surname>Galinski</surname><given-names>MR</given-names></name><name name-style="western"><surname>Baird</surname><given-names>JK</given-names></name><etal/></person-group>
<article-title>Key gaps in the knowledge of <italic>Plasmodium vivax</italic>, a neglected human malaria parasite</article-title>. <source>Lancet Infect Dis</source>
<year>2009</year>; <volume>9</volume>:<fpage>555</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">19695492</pub-id></mixed-citation></ref></ref-list></back></article>